Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal

Pharmacol Toxicol. 1990 Oct;67(4):273-83. doi: 10.1111/j.1600-0773.1990.tb00830.x.


Polymorphic oxidation of the sparteine/debrisoquine-type has been shown to account for much of the interindividual variation in the metabolism, pharmacokinetics and pharmacodynamics of an increasing number of drugs, including some antiarrhythmic, antidepressant and beta-adrenoceptor antagonist agents. Impaired hydroxylation of these drugs results from the absence of the enzyme cytochrome P450IID6 in the livers of poor metabolisers, who constitute 6% to 10% of Caucasian populations. The clinical importance of the phenomenon has to be explored further and for most sparteine/debrisoquine-related substrates there is a need for controlled prospective studies to define the consequences to the patient of impaired or enhanced drug oxidation.

Publication types

  • Review

MeSH terms

  • Animals
  • Debrisoquin / metabolism*
  • Humans
  • Oxidation-Reduction
  • Polymorphism, Genetic / physiology*
  • Sparteine / metabolism*


  • Sparteine
  • Debrisoquin